Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

Prostate Cancer

California HIFU and Dr. Michael Lazar Recognizes Men’s Health Month With a Look at Prostate Cancer

California HIFU and Dr. Michael Lazar are helping to recognize Men’s Health Month by providing some valuable information and resources for men on Prostate Cancer. The idea behind Men’s Health Month is to heighten the awareness of preventable health problems like prostate cancer, and to encourage early detection and treatment. Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU, a medical procedure that applies high-intensity focused ultrasound energy to locally heat and destroy diseased or damaged tissue with prostate cancer through ablation.

Informed Decision Making

your-questions-answeredAccording to The Center for Disease Control and Prevention (CDC) it is important for men to be aware of prostate cancer risks and to make informed decisions. This happens best when a man—

  • Understands the nature and risk of prostate cancer.
  • Understands the risks of, benefits of, and alternatives to screening.
  • Participates in the decision to be screened or not at a level he desires.
  • Makes a decision consistent with his preferences and values.

The CDC as well as other federal agencies follow the prostate cancer screening recommendations set forth by the U.S. Preventive Services Task Force, which recommends against prostate specific antigen (PSA)-based screening for men who do not have symptoms. Other organizations, like the American Urological Association,[PDF-310KB] the American Cancer Society, and the American College of Physicians may have other recommendations. It is important to talk to a doctor and get routine screenings.

Some men may be having prostate problems and want to learn more about prostate cancer symptoms and risk factors, the PSA screening test, and conditions that are not cancer such as an enlarged prostate (BPH) and prostatitis. To learn more follow this link for practical lists, tips, and medical images …

Knowing your prostate cancer therapy options empowers you to make smart choices

Prostate cancer is the leading solid organ cancer in the USA and the second most common cause of cancer related death. Worldwide, it is the fourth most common cancer with differing biologic activity in different cultures, probably related to different lifestyles. Many prostate cancers can be managed conservatively, especially in elderly men. But larger tumors, those with higher Gleason score and higher (and rising) PSA levels, especially in younger men, should be treated more aggressively.

Prostate Cancer Therapy Options

There are many options available to residents of Northern California. Prostate cancer is usually managed with active surveillance, radiation therapy, surgery to remove the cancerous gland, freezing (cryotherapy), or high intensity focused ultrasound (HIFU). Hormonal therapy is used to control cancer that has spread beyond the prostate and is no longer curable, or for very elderly patients with a limited life expectancy.

High Intensity Focused Ultrasound (HIFU)

HIFU is a FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation.

HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. However, at the focal point of the sound waves (like a magnifying glass focusing the rays of the sun to burn a leaf), the tissue temperature is raised to 90 degrees Celsius, destroying the targeted tissue.

Learn more about HIFU treatment for prostate cancer …

By | June 14th, 2016|News, Prostate Cancer|0 Comments

Focal Therapy For Prostate Cancer

hifu mini article cropped-logo-square.jpgFocal therapy, often referred to as a “male lumpectomy,” is a general term for a variety of noninvasive techniques for destroying small tumors inside the prostate while leaving the gland intact and sparing most of its normal tissue

As technology has advanced, physicians now have the ability to diagnose patients with prostate cancer earlier which means that often times tumors within the prostate are small and contained to the prostate.

Advanced imaging techniques, allow doctors to pinpoint exactly where the tumor within the prostate is located using multi-parametric MRI and UroNav fusion biopsies, enabling them to target only the tumor within the prostate, leaving other tissue unharmed.

Focal therapy is being studied all over the world because of the large potential for reducing side effects such as urinary incontinence and erectile dysfunction. Additionally, due to the noninvasive nature of focal therapy, treatment and recovery times are dramatically reduced.

Read this article on HIFU Prostate Services.

For more information about HIFU treatment which is now available in San Francisco, or to make an appointment call: (707) 546-5553. Visit us online to learn more at: www.californiahifu.com.

Santa Rosa Urologist Dr. Michael Lazar is Making History with a Nonsurgical, Outpatient Treatment for Prostate Cancer

Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU.

Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU.

High-intensity focused ultrasound (HIFU) waves target cancer cells with precision in a one-to-four-hour procedure that has little or no side affects and a quick recovery rate, giving those diagnosed with prostate cancer another choice over surgery or radiation.

HIFU has been used in other countries for years, and Dr. Lazar has been instrumental in bringing this innovative treatment to the United States. It was approved by the Food and Drug Administration last October, and he has since been performing the procedure at San Francisco Surgery Center for patients who travel from across the country to receive this leading edge treatment.

“The oncological results for HIFU are broadly comparable to radical surgery or radiation but the side effects are less,” says Dr. Lazar. “If the HIFU procedure is performed in the morning, a patient is typically up and around by dinnertime and can often return to normal activity within a few days without the use of pain-killers.”

Dr. Lazar has recently become involved with HIFU Prostate Services, LLC as their Medical Director.  HIFU Prostate Services is the first company to establish centers in the United States offering Sonablate HIFU technology. HIFU Prostate Services makes the non-invasive treatment option available through partnerships with some of the largest urology practices and experienced physicians that establish Sonablate HIFU Centers of Excellence.  Urologists are able to create their own HIFU program and offer treatment within their region. These centers also offer training and proctorship opportunities.

Along with serving as the Medical Director of HIFU Prostate Services, LLC. Dr. Lazar is also a clinical partner with his HIFU Center of Excellence at the state-of-the-art SFSC in downtown San Francisco. Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU. He has worked tirelessly with SonaCare, the manufacturer of the instruments, to bring this innovative service for prostate cancer treatment to patients in the United States.

The HIFU technique is also being developed to treat many other types of cancer including breast, uterine, liver, kidney, and brain.

For those with prostate cancer, HIFU treatment is most effective for patients with early stage cancer, where it is localized to the prostate. It is performed on an out-patient basis that takes one to four hours. A urinary catheter is placed after the procedure for one to three weeks.

While some patients might experience slight irritation, “some patients can have a catheter and they don’t even know it.”

The procedure preserves healthy tissue and nerves, so urine flow and erectile function is maintained in a high percent of cases, as compared to radical surgery or radiation.

Another advantage is recovery time. With surgery or radiation treatment, recuperation time for patients is six to eight weeks, whereas HIFU patients return to normal activities within days.

Dr-michael-lazarDr. Lazar has been treating U.S. prostate cancer patients in Mexico since 2007, where he performed hundreds of outpatient procedures at a U.S. Joint Commission approved bilingual hospital. There, he also served as a HIFU instructor for other physicians and is now training doctors in San Francisco.

Because the treatment is so new, it will take another couple of years before it will be routinely covered by insurance. Those with non-Medicare insurance may get reimbursed to varying degrees.

“What will really make this explode is when the insurance companies are routinely covering the procedure and it will become widely available to all patients. The costs for this procedure are drastically less than for radical surgical and radiation procedures, and with fewer complications so insurance companies will be incentivized to cover it,” Dr. Lazar commented.

As soon as more doctors are trained to perform the procedure in San Francisco, Dr. Lazar plans to bring the treatment to his Santa Rosa office.

“I expect as word gets out there will be a progressive demand for this procedure, so training physicians will be a high priority. It’s already expanding rapidly and we put in an order for our tenth machine,” said Dr. Lazar, adding he won’t be giving up his general urology practice any time soon. “This is what I love to do.”

 

 

 

Prostate cancer treatment which avoids harming sexual performance soon available on NHS

A revolutionary prostate cancer treatment which avoids harming men’s sexual performance could soon be available on the NHS.

High Intensity Focused Ultrasound kills the tumour with heat without damaging healthy tissue around it.

In an NHS trial led by University College Hospital, London, 625 men were treated. After five years 93% were cancer-free.

Only 15% had erectile problems compared with 30 to 60% following surgery.

The results were revealed to the European Association of Urology in Munich.

 

Read the full story …

By | April 5th, 2016|HIFU, News, Prostate Cancer, Testimonials|0 Comments

Prostate cancer targeted with ultrasound ‘could transform treatment’

man-at-lake-1374960The study – on the effectiveness of high-intensity focused ultrasound (HIFU) to treat men with localized prostate cancer – featured at the European Association of Urology Congress (EAU16) in Munich, Germany, March 11-15, 2016.

Led by University College Hospital (UCH) in London, UK, the study followed 625 men between 2004-2015, who were treated in the UK and who had localized, non-metastatic tumors; the tumors were in one part of the prostate and had not spread beyond the gland.

Hashim Ahmed, a consultant urological surgeon at UCH, told the meeting that 93% of patients who underwent HIFU alone to remove their prostate tumor were still cancer-free and did not need any surgery or radiotherapy 5 years after treatment. The results follow those of an earlier study by Ahmed and colleagues published in The Lancet Oncology in 2012, where, of 41 men who underwent HIFU, 95% were free of cancer after 12 months. Not one of the patients developed incontinence, and only 1 in 10 suffered erectile dysfunction.

In the new, larger study, which reports medium-term results, only 1-2% of the HIFU patients experienced long-term incontinence, and just 15% suffered erectile dysfunction. These figures compare favorably with men who have surgery, where around 30-60% experience these distressing side effects. Read the full story …

By | March 29th, 2016|Dr. Michael Lazar, HIFU, News, Prostate Cancer|0 Comments

Best-selling Author John Grisham Turns HIFU Advocate

John Grisham Turns Promoter for Focused Ultrasound (HIFU)

Takes a break from legal thrillers to tout HIFU’s benefits

Best-selling author John Grisham has a side job.

When the legal thriller writer is taking a break from stories of tort reform and multi-million dollar trials, or of small town justice gone awry and blackmailed jurors — or any of the other legal topics he’s covered in the roughly one book a year he’s written since 1988 — he thinks about high-intensity focused ultrasound.

Or rather, he’s busy raising money and awareness for the technology as part of the Focused Ultrasound Foundation, where he sits on the board. He “still doesn’t understand the technology” behind focused ultrasound, he said in a recent TEDx Talk in Charlottesville, Va., but nevertheless advocates for it because he’s found “no other cause, issue, non-profit, or charity that can potentially save so many lives.”

Grisham’s latest effort to get more eyes on, and more money for, the foundation is The Tumor: A Non-Legal Thriller, a 67-page book that tells the story of a man with glioblastoma. It includes diagrams of the procedure and pictures of an actual glioblastoma, and it’s available for free as an Amazon Single, where it was sitting at #16 on the most popular free Kindle Single list at the time of writing.

Read the full story here …

By | March 1st, 2016|Dr. Michael Lazar, News, Prostate Cancer|0 Comments

Minimally Invasive Prostate Cancer Treatment HIFU Now Available in the U.S.

sonablate500After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence which are typically reported with surgery and radiation.

HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Newly appointed HPS Medical Director Michael J. Lazar, MD is set to provide medical guidance and proctoring to new physicians who will now be trained on the Sonacare® HIFU system in surgery centers around the country. Dr. Lazar has been treating patients with HIFU since 2007 and is one of only three U.S. physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.

John W. Linn, chief executive officer of HPS commented, “I have known Dr. Lazar since 2007 and have been impressed with his patient care and dedication to the HIFU technology since his first treatment. He is the ideal medical director for HPS and for teaching this new technology to US physicians.”

Lazar will also operate his own HIFU Program in partnership with HPS, offering prostate treatments in downtown San Francisco near Union Square at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility that is convenient to hotels and the airport for patients interested in traveling from around the country for HIFU treatments. The actual Sonablate device has just been delivered to the Surgery Center in San Francisco, marking the first time ever that a HIFU device will be available at a medical center in the United States.

“It is very exciting to be a part of providing the vehicle for access to this technology for new and experienced HIFU users. Over the years, physicians in various stages of training have shown remarkable enthusiasm for providing HIFU for their prostate cancer patients, but they did not see a clear path for obtaining accessibility to the technology after FDA approval,” said Lazar. “HIFU Prostate Services takes the mystery and tedium out of the process by providing the highest quality of care, support and technology to the patient and to the urology community. Men who choose HIFU can contact HPS and then be referred to a regional HIFU surgeon. This approach facilitates wide availability of this treatment option for American men.”

HIFU offers patients a single, outpatient treatment for prostate cancer that is bloodless and allows men to return to their normal lifestyles within a few days. Although HIFU is designed as a single treatment, it can be repeated if needed. HIFU may also be used to treat patients that have failed radiation therapy and it does not preclude any future treatments including surgery or radiation.

About HIFU Prostate Services, LLC & Dr. Michael Lazar

At HIFU Prostate Services (HPS), our mission is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS was founded in 2015 by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies The company is headquartered in Charlotte, N.C.

lazar close up

Dr. Michael Lazar

Dr. Michael Lazar has been certified by the American Board of Urology four times and has practiced in Santa Rosa, California since 1983. He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

For additional information, visit Dr. Michael Lazar at www.californiahifu.com, 707-546-5553 or www.hifuprostateservices.com. Media Contact: John Linn, 704-737-5925
.

HIFU Now Available In the U.S. Ending a Long Awaited FDA Approval Process

sonablate500After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence which are typically reported with surgery and radiation.

HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Newly appointed HPS Medical Director Michael J. Lazar, MD is set to provide medical guidance and proctoring to new physicians who will now be trained on the Sonacare® HIFU system in surgery centers around the country. Dr. Lazar has been treating patients with HIFU since 2007 and is one of only three U.S. physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.

John W. Linn, chief executive officer of HPS commented, “I have known Dr. Lazar since 2007 and have been impressed with his patient care and dedication to the HIFU technology since his first treatment. He is the ideal medical director for HPS and for teaching this new technology to US physicians.”

Dr. Lazar will also operate his own HIFU Program in partnership with HPS, offering prostate treatments in downtown San Francisco near Union Square at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility that is convenient to hotels and the airport for patients interested in traveling from around the country for HIFU treatments. The actual Sonablate device has just been delivered to the Surgery Center in San Francisco, marking the first time ever that a HIFU device will be available at a medical center in the United States.

“It is very exciting to be a part of providing the vehicle for access to this technology for new and experienced HIFU users. Over the years, physicians in various stages of training have shown remarkable enthusiasm for providing HIFU for their prostate cancer patients, but they did not see a clear path for obtaining accessibility to the technology after FDA approval,” said Lazar. “HIFU Prostate Services takes the mystery and tedium out of the process by providing the highest quality of care, support and technology to the patient and to the urology community. Men who choose HIFU can contact HPS and then be referred to a regional HIFU surgeon. This approach facilitates wide availability of this treatment option for American men.”

HIFU offers patients a single, outpatient treatment for prostate cancer that is bloodless and allows men to return to their normal lifestyles within a few days. Although HIFU is designed as a single treatment, it can be repeated if needed. HIFU may also be used to treat patients that have failed radiation therapy and it does not preclude any future treatments including surgery or radiation.

About HIFU Prostate Services, LLC & Dr. Michael Lazar

At HIFU Prostate Services (HPS), our mission is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS was founded in 2015 by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies The company is headquartered in Charlotte, N.C.

lazar close upLazar has been certified by the American Board of Urology four times and has practiced in Santa Rosa, California since 1983. He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

For additional information, visit Dr. Michael Lazar at www.californiahifu.com, 707-546-5553 or www.hifuprostateservices.com. Media Contact: John Linn, 704-737-5925

By | November 10th, 2015|Dr. Michael Lazar, HIFU, Prostate Cancer|0 Comments

High Intensity Focused Ultrasound (HIFU) Therapy is Gaining International Acceptance for the Treatment of Medical Conditions

your-questions-answeredA growing number of international medical organizations have already adopted High Intensity Focused Ultrasound (HIFU) therapy for treating an increasing number of conditions, and as a viable option to traditional invasive surgery, according to Dr. Michael Lazar, a Santa Rosa, California-based Urologist and a leading advocate for HIFU as an effective treatment for prostate cancer.

Dr. Lazar states, “The scientific community has known for years that high heat kills cancer. But only in recent years has the science advanced to the point where focused ultrasound energy can be used to provide pinpoint accuracy, sparing healthy tissue and preserving nerves, urine flow and erectile function in a majority of cases compared with traditional procedures, while also delivering the required amount of heat needed to destroy, or ablate, cancer.”

Today HIFU is being deployed around the world, especially in Europe, for the treatment of abdominal kidney tumors, urological cancers, uterine fibroids, and to relieve neuropathic pain associated with bone cancer, in addition to being a non-invasive treatment for prostate cancer. Medical literature also reports the use of HIFU in treating liver, breast and brain tumors as well as other conditions.”

For example, according to the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) located in Vienna, Austria, positive results were achieved with transcranial Magnetic Resonance MR-guided focused ultrasound surgery (tcMRgFUS) as a non-invasive treatment of essential tremors, neuropathic pain and Parkinson’s disease. CIRSE also reports that there have also been some investigations into the use of HIFU for temporarily opening the blood-brain barrier, allowing absorption of drugs into the brain.

Furthermore, a minimally invasive catheter-based HIFU system — designed to ablate heart tissue responsible for atrial fibrillation — has been approved for use in Europe and is undergoing an FDA approved trial in the United States.

“Adoption of HIFU has proceeded at a faster rate among international medical communities than in the United States, however, there are hopeful signs that this technique will soon be available to a broader range of patients here at home so they will not have to travel to hospitals outside of the U.S. to take advantage of this procedure,” Dr. Lazar said.

For more information about Dr. Michael Lazar, go to the HIFU website or call (707) 546-5553. His office is located at 1140 Sonoma Ave #1A, in Santa Rosa, CA 95405.

Indianapolis, Indiana-based SonaCare Medical LLC, a leading developer of minimally-invasive HIFU technology, is bringing several HIFU systems to market to meet growing global demand. SonaCare Medical, LLC, serves customers around the world through its family of affiliate companies including: USHIFU, International HIFU and Focus Surgery. For additional information, go to: www.sonacaremedical.com.

September is Prostate Cancer Awareness Month

Get a Checkup, Have a PSA Blood Test and Learn About Symptoms of the Disease as well as Treatment Options

Prostate cancer is the second leading cause of death following lung cancer, and about one man in 38 will die of the disease. However, statistics show that most men diagnosed with the prostate cancer do not die from it, and more than 2.9 million men in the U.S. who were found to have this cancer are alive today. But why take a chance? A simple screening involving an annual blood test to measure PSA levels gives doctors a way to assess the presence and pace of the disease and the need for ongoing monitoring, a biopsy or direct intervention.September is national Prostate Cancer Awareness Month. About 220,800 new cases of this type of cancer are reported each year, along with 27,540 deaths attributed to the disease annually. One in seven men will be diagnosed with prostate cancer during their lifetime. While only one man in 10,000 will typically get prostate cancer under age 40, the risk increases to six of every 10 men by age 65, according to the American Cancer Society.

Prostate cancer is the second leading cause of death following lung cancer, and about one man in 38 will die of the disease. However, statistics show that most men diagnosed with the prostate cancer do not die from it, and more than 2.9 million men in the U.S. who were found to have this cancer are alive today. But why take a chance? A simple screening involving an annual blood test to measure PSA levels gives doctors a way to assess the presence and pace of the disease and the need for ongoing monitoring, a biopsy or direct intervention.

“Why is there such a difference between cancers? Some prostate cancer is very aggressive and progresses quickly, while other forms take many years to become life threatening,” said Michael Lazar, a noted urologist with a practice in Santa Rosa, California and a leading proponent of non-invasive High Intensity Focused Ultrasound (HIFU) therapy for prostate cancer treatment.

You have a number of options if it is determined that you have this disease. These include traditional surgery to remove the prostate gland, radiation (including inserting irradiated pellets into the prostate), cryotherapy (freezing of the prostate), or non-invasive HIFU therapy using sound waves to pinpoint cancer cells and destroy them without damage to surrounding healthy tissue and minimal blood loss.

Side effects associated with invasive surgical procedures including a hospital stay, a longer recovery period plus scaring, adhesions and blood loss. There is also the risk of incontinence, erectile dysfunction (ED) and a decline of libido. Radiation can ionize otherwise healthy cells that can turn into cancer latter in life. With cryotherapy, side effects include 90% to 100% ED and urethral tissue scaring that can obstruct voiding. The HIFU procedure is virtually painless, takes only a few hours, and there are fewer side effects, thereby maintaining the quality of life. Most patients are up and around the same day.

In most instances, there are no significant symptoms during the early stages of prostate cancer, and symptoms may vary from one man to another, or can be caused by other conditions. However, there are some urinary symptoms that could signal cancer including: pain or a burning sensation while urinating as well as difficulty in starting or stopping, frequent urges to go during the night, an uncontrollable bladder, a decreased flow of the urine stream, or blood in the urine. Other symptoms include painful ejaculation or difficulty in getting an erection, swelling in the legs or pelvic area, pain or numbness in the feet, legs or hips, constant bone pain leading to fractures and blood in the semen.

“My advice to every man is to obtain a baseline PSA after age 40, then yearly exams and PSA tests after 50 years of age. For those having to make a treatment choice for prostate cancer, consider all options including HIFU. While not currently available in the U.S., HIFU is pending FDA approval and is available internationally at a full-service hospital in Puerto Vallarta, Mexico, where dozens of successful HIFU procedures have been performed by me and my highly trained team,” Dr. Lazar said.

For additional information, go to the website at www.californiahifu.com, or contact Dr. Michael Lazar’s office at (707) 546-5553. His office is located at 1140 Sonoma Ave #1A, Santa Rosa, CA 95405.